Summary of various treatment modalities utilized for patients with COVID-19 infection complicated with aortic thrombus and overall outcomes
Treatment modality | Favorable outcome | Unknown outcome | Mortality |
---|---|---|---|
Anticoagulation only (n = 14, 32.5%) | 57% (n = 8) | 7% (n = 1) | 35% (n = 5) |
Anticoagulation with antiplatelet therapy (n = 3, 6.9%) | 100% (n = 3) | 0% | 0% |
Medical management (not reported specifically) (n = 7, 16.2%) | 42% (n = 3) | 28% (n = 2) | 28% (n = 2) |
Systemic thrombolysis (n = 2, 4.6%) | 50% (n = 1) | 50% (n = 1) | n = 0 |
Surgical thrombectomy (n = 9, 20.9%) | 77.7% (n = 7) | n = 0 | 22.3% (n = 2) |
Axillobifemoral bypass surgery (n = 2) | 50% (n =1) | n = 0 | 50% (n = 1) |
Catheter directed thrombolysis (n = 2, 4.6%) | 50% (n = 1) | 50% (n = 1) | n = 0 |
Endovascular thrombectomy (n = 1, 2.3%) | n = 0 | 100% (n = 1) | n = 0 |
Catheter directed thrombolysis with surgical thrombectomy (n = 1, 2.3%) | 100% (n = 1) | n = 0 | n = 0 |
Systemic thrombolysis with surgical thrombectomy (n = 1, 2.3%) | n = 0 | n = 0 | 100% (n = 1) |
JM and KK contributed conception and design of the study; KA and AA organized the database; AA performed the statistical analysis; KK wrote the first draft of the manuscript; AA wrote results section, JM, KK and AA wrote introduction and discussion sections. JM provided overall supervision for this study. All authors contributed to manuscript review, and read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Informed consent to publication was obtained from relevant participants.
Data can be provided upon request from the responding author.
Not applicable.
© The Author(s) 2021.